No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 886,245 | 971,296 | 1,161,588 | 1,546,000 | 2,061,052 | 2,768,952 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | -48,817 | -51,709 | -40,024 | -16,189 | 45,675 | 73,748 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Duta Intidaya Tbk operates as a prominent health and beauty retailer throughout Indonesia, offering a diverse product portfolio. Its offerings span pharmaceutical products, including medicines and various pharmacy goods, alongside medical and wellness devices. The company also supplies personal care and skincare items, fragrances, cosmetics, infant products, and a selection of general merchandise. Furthermore, it engages in the trade of food and beverage items. Beyond its retail activities, PT Duta Intidaya Tbk undertakes various roles within the supply chain, serving as an agent, sole representative, distributor, purveyor, franchisor, and supplier for a wide array of traded goods. As of December 31, 2021, the company maintained a significant physical presence with 160 Watsons-branded stores spread across 14 provinces. Its digital reach is extensive, providing products through major e-commerce platforms like Shopee.com, Tokopedia.com, Lazada.com, Blibli.com, and Bukalapak.com, as well as via applications such as Halodoc, Bima+, Good Doctor, GrabMart, and GoMart. Established in 2005 and headquartered in South Jakarta, Indonesia, the company is a subsidiary of Total Alliance Holdings Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Duta Intidaya Tbk (DAYA.JK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PT Duta Intidaya Tbk operates as a prominent health and beauty retailer throughout Indonesia, offering a diverse product portfolio. Its offerings span pharmaceutical products, including medicines and various pharmacy goods, alongside medical and wellness devices. The company also supplies personal care and skincare items, fragrances, cosmetics, infant products, and a selection of general merchandise. Furthermore, it engages in the trade of food and beverage items. Beyond its retail activities, PT Duta Intidaya Tbk undertakes various roles within the supply chain, serving as an agent, sole representative, distributor, purveyor, franchisor, and supplier for a wide array of traded goods. As of December 31, 2021, the company maintained a significant physical presence with 160 Watsons-branded stores spread across 14 provinces. Its digital reach is extensive, providing products through major e-commerce platforms like Shopee.com, Tokopedia.com, Lazada.com, Blibli.com, and Bukalapak.com, as well as via applications such as Halodoc, Bima+, Good Doctor, GrabMart, and GoMart. Established in 2005 and headquartered in South Jakarta, Indonesia, the company is a subsidiary of Total Alliance Holdings Limited.